三级诊所中银屑病的治疗费用。
Treatment costs of psoriasis in a tertiary-level clinic.
作者信息
Mustonen Anssi, Leino Mauri, Mattila Kalle, Koulu Leena, Tuominen Risto
机构信息
Department of Dermatology, Turku University Hospital and University of Turku, Turku, Finland.
出版信息
BMC Health Serv Res. 2014 Aug 15;14:344. doi: 10.1186/1472-6963-14-344.
BACKGROUND
The costs of psoriasis to a tertiary-level clinic vary considerably depending on the country of study and methods used. Hospitalisation and phototherapy have been significant cost components. This study was performed to estimate the distribution and relative magnitude of the costs of psoriasis to a tertiary-level clinic.
METHODS
Based on 233 patients, outpatient and phototherapy visits and the days hospitalised were collected from the treatment provider's records. The visit costs represented true costs, used to charge the final payers. Patients were analysed according to their treatment modalities.
RESULTS
On average, hospitalised patients (3.4%) had 31-fold higher total costs than non-hospitalised patients (p < 0.0001). The costs of hospitalisations formed 45% of all the treatment costs to the entire study population. Phototherapy accumulated 19% of the overall treatment costs. Patients receiving biological drugs or both phototherapy and traditional systemic therapy had the highest costs of treatment.
CONCLUSIONS
The current study indicates that a small percentage of all psoriasis patients generate a large proportion of the overall costs to a tertiary-level hospital. Treatment modality has a significant effect on the costs to a tertiary-level hospital.
背景
银屑病在三级诊所的花费因研究国家和所采用的方法不同而有很大差异。住院治疗和光疗一直是重要的费用组成部分。本研究旨在估算银屑病在三级诊所的费用分布及相对规模。
方法
基于233例患者，从治疗机构记录中收集门诊和光疗就诊次数以及住院天数。就诊费用代表实际成本，用于向最终支付方收费。根据治疗方式对患者进行分析。
结果
平均而言，住院患者（3.4%）的总费用比非住院患者高31倍（p < 0.0001）。住院费用占整个研究人群所有治疗费用的45%。光疗费用占总治疗费用的19%。接受生物制剂治疗或同时接受光疗和传统全身治疗的患者治疗费用最高。
结论
当前研究表明，所有银屑病患者中一小部分产生了三级医院大部分的总体费用。治疗方式对三级医院的费用有显著影响。
Zotero 插件